the 15th international symposium on anti-angiogenic therapy: recent advances and future directions...
DESCRIPTION
TRANSCRIPT
ANGIO2013
The 15th International Symposium on Anti-Angiogenic Therapy:Recent Advances and Future Directions in Basic and Clinical Cancer Research
January 31–February 2, 2013
Hyatt Regency La Jolla • 3777 La Jolla Village Drive • San Diego, California
www.antiangio2013.comFor Information and Poster Submission Form
EvaluationA course evaluation form will provide participants with the opportunity to comment on the value of the program content to their practice decisions, performance improve-ment activities, or possible impact on patient health status. Participants will also have the opportunity to comment on any perceived commercial bias in the presentations as well as to identify future educational topics.
Accreditation/Credit DesignationThe University of Texas MD Anderson Cancer Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The University of Texas MD Anderson Cancer Center designates this live activity for a maximum of 14.50 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CME Certificates and Attendance Verification CertificatesCertificates awarding AMA PRA Category 1 CreditTM or certificates documenting attendance will be distributed to participants when an individual departs the conference. To obtain a CME certificate, physicians must submit a completed evaluation questionnaire and a CME Verification Form.
Upon request, a record of attendance (certificate) will be provided on-site to other health care professionals for requesting credits in accordance with state nursing boards, specialty societies, or other professional associations.
POSTER SUBMISSION/ SESSION:The symposium will feature a poster session where academics and investigators from the industry present angiogenesis-related data from both clinical trials and laboratory research. Trainees are especially encouraged to present their research. Accepted posters will be displayed with ample time for viewing and discussions
All symposium participants, including members of industry, are encouraged to present research data as part of the poster session.
The deadline for submitting poster applications is Friday, December 14, 2012.
Please check the website for more information and the submission form at www.antiangio2013.com.
Program OverviewAngiogenesis is an essential process in the growth of neoplasms and progression to metastasis. The angiogenic pathway is orchestrated by a range of pro- and anti-angiogenic factors that ultimately lead to the development of a neovascular blood supply to the tumor mass. Vascular endothelial growth factor (VEGF), which stimulates proliferation and migration of endothelial cells, plays a pivotal role in this process. For these reasons, the inhibition of VEGF and its receptor signaling system are attractive targets for therapeutic intervention. Indeed, the approval in 2004 of a neutralizing monoclonal antibody directed against VEGF – the first anti-angiogenic systemic drug to treat cancer patients-validated the notion introduced decades earlier that inhibition of tumor angiogenesis may be a valid approach to control tumor growth. This success has driven the search for new anti-angiogenic agents. For example, small-molecule multikinase inhibitors that target VEGF receptors have recently demon-strated efficacy in multiple tumor types. A number of other anti-angiogenic agents targeting an increasing variety of molecular tumor features are in clinical development. More recently, studies of powerful new genetic and cell biological approaches have provided unprecedented insights into how various molecular are pivotal to tumor growth and survival. As a consequence, a number of new angiogenic molecules, such as neuropilins, Tie-2, and Notch ligand delta-like 4, have emerged as promising targets.
Since its inception over 4 decades ago, investigators in the field of tumor angiogenesis research have made significant progress. Advancements in therapeutics have altered cancer treatment paradigms, and the next decade promises to be an exciting and productive time. This annual state-of-the-art symposium is designed to continue the dialogue and interaction between research and clinical investigators by reviewing the current scientific understanding of vascular biology and angiogenesis. In addition, this symposium provides a forum for presenting the most current preclinical and clinical data on emerging anti-angiogenic agents and regimens. Strategies that inhibit angiogenesis in colorectal, breast, lung, esophageal, gastric, genitourinary, neuroendocrine, central nervous system, hepatocellular and gynecologic malignancies will be discussed. In addition, biomarkers and resistance pathways will be addressed and controversies in the field will be highlighted.
Educational ObjectivesAfter attending the symposium, participants should be able to• Defineangiogenesisanditsrelevancetothetreatmentofcancer(Knowledge);• Outlinetherationaleforthedevelopmentofanti-angiogeneicagents,andexplainwhy
angiogenic signaling pathways are targets for inhibition (Knowledge);• Summarizedatafromclinicaltrialsthatsupporttheuseofcurrentlyavailableanti-angiogenic
agents as monotherapy or in combination with other therapeutic modalities, which will ultimately assist the healthcare provider to make appropriate clinical decisions (Knowledge, Competence, Performance, Patient Outcomes);
Target AudienceThis symposium is designed for medical, surgical, and radiation oncologists, pharmacists, other providers of cancer care (PAs, RNs, etc.), and research scientists who have an interest in the biology, diagnosis, and treatment of cancer, as well as those who diagnose and treat patients with nonmalignant vascular diseases, such as arthritis and retinal neovascularization. As new and emerging data on anti-angiogenic therapy is presented at this symposium every year, it is necessary for this audience to be made aware of these findings so they can be utilized in their clinical practice.
Educational MethodsLectures–PanelDiscussions–QuestionandAnswer–PosterSession
Lee M. Ellis, MDProfessor of Surgery and Cancer BiologyWilliam C. Liedtke, Jr., Chair in Cancer ResearchThe University of Texas MD Anderson Cancer CenterHouston, Texas
Robert S. Kerbel, PhDCanada Research Chair in Tumor Biology, Angiogenesis and Anti-Angiogenic TherapyUniversity of TorontoProfessor, Molecular and CellularBiology ResearchSunnybrook Health Sciences Centre/Odette Cancer CentreToronto, Ontario, Canada
George W. Sledge, Jr., MDBallve-Lantero Professor of OncologyCo-Director, Breast Cancer ProgramIndiana University Melvin and Ben Simon Cancer CenterIndianapolis, Indiana
Helen X. Chen, MDSenior Investigator in Cancer TherapyEvaluation ProgramNational Cancer InstituteRockville, Maryland
Axel Grothey, MDProfessor of OncologyDivision of Medical OncologyMayo Clinic Division of Medical OncologyRochester, Minnesota
Planning Committee
Wednesday, January 30, 20133:00–7:00 p.m. Registration
Thursday, January 31, 20137:30–8:00 a.m. Registration/Continental Breakfast
Session I: Basic Biology and Preclinical Data Moderator:LeeM.Ellis,MD;RobertS.Kerbel,PhD
8:00–8:30 Opening Remarks/Overview LeeM.Ellis,MD 8:30–8:55 Combinatorial Targeting of Endothelial Growth Factors and Receptors KariAlitalo,MD,PhD 8:55–9:20 Tumor Hypoxia: Is Targeting HIF a Viable Approach? M.CelesteSimon,PhD 9:20–9:45 Metronomic Chemotherapy with Anti-Angiogenic Drugs:
An Update RobertS.Kerbel,PhD 9:45–10:10 Resistance to VEGF-Targeted Therapies TBD
10:10–10:30 Break 10:30–10:55 Anti-Angiogenic Agents Stimulate Breast Cancer
Stem Cells via Generation of Tumor Hypoxia MaxS.Wicha,MD 10:55–11:10 Abstract #1 11:10–11:35 The Role of SDF-1/CXCR4 Signaling in Angiogenesis MartinBrown,DPhil 11:35–Noon Oscillation of Immune Cells in Response to
Anti-Angiogenic Therapy GabrieleBergers,PhD Noon–1:00 p.m. Lunch
Program Session II: Biomarkers and ImagingModerator:RobertS.Kerbel,PhD
1:00–1:25 Predictive Biomarkers: VEGF Amplifications and Host Polymorphisms
BryanP.Schneider,MD1:25–1:50 Predictive Biomarkers: Imaging and Circulating VEGF GordonJayson,MD,PhD1:50–2:05 Abstract #22:05–2:30 Standardizing Imaging Criteria to Assess the Effect of Anti VEGF Therapy in Brain Tumors BradleyJ.Erickson,MD,PhD2:30–2:55 The FDA Pre-IDE Process:
Lessons Learned for Integral Markers J.MilburnJessup,MD2:55–3:15 Break3:15–3:45 Panel Discussion: Implementation of Biomarkers Moderator:LeeM.Ellis,MD Panelists:S.GailEckhardt,MD;BradleyJ.Erickson,MD,PhD;
AxelGrothey,MD;GordonJayson,MD,PhD; J.MilburnJessup,MD;BryanP.Schneider,MD
3:45–5:30 p.m. Poster Reception
Friday, February 1, 20137:30–8:00 a.m. Registration/Continental Breakfast
Session III: Controversies and New HorizonsModerators:AxelGrothey,MD;GeorgeW.Sledge,Jr.,MD
8:00–8:05 Introduction GeorgeW.Sledge,Jr.,MD
8:05–8:25 Is RECIST Still Relevant in the Era of VEGF Inhibition Through Multiples Lines of Therapy?
Implications for Clinical Trial Design in All Malignancies AxelGrothey,MD
8:25– 8:50 Patient Derived Xenograft Models: Are They Appropriate For Anti-Angiogenic and Microenvironment Therapies? S.GailEckhardt,MD
8:50–9:15 From the Laboratory to the Labrador: Spontaneous Canine Cancer as a Model for Anti-Angiogenic Drug Development DouglasH.Thamm,VMC,DACVIM
9:15–9:40 Promise and Pitfalls of Anti-Angiogenic Therapy in the Adjuvant Setting
DanielF.Hayes,MD
9:40–10:00 Break
Session IV: Early Drug DevelopmentModerators:HelenX.Chen,MD;GeorgeW.Sledge,Jr.,MD
10:00–10:15 Early Drug – Phase I MichaelS.Gordon,MD
10:15–10:30 Early Drug – Phase I LeeS.Rosen,MD
10:30–10:45 Abstract #3
10:45–11:00 A Phase I Clinical Trial of VX15/2503, A Novel Humanized IgG4 Anti-SEMA4D Antibody, In Patients With Advanced Solid Tumors
AmitaPatnaik,MD
11:00–11:25 The Role of CTEP in the Development of Angiogenesis Inhibitors
HelenX.Chen,MD
11:30–12:30 p.m. Lunch
Session V: Clinical Trial ResultsModerator:HelenX.Chen,MD;MichaelS.Gordon,MD
12:30-12:55 Anti-Angiogenic Therapy for the Treatment of Hepatocellular Carcinoma
GhassanK.Abou-Alfa,MD
12:55–1:20 Anti-Angiogenic Therapy for the Treatment of Sarcoma GaryK.Schwartz,MD
1:20–1:45 Anti-Angiogenic Therapy for the Treatment of Ovarian Cancer GordonJayson,MD,PhD
1:45–2:05 Break
2:05–2:30 Anti-Angiogenic Therapy for the Treatment of Colorectal Cancer
CharlesD.Blanke,MD
2:30–2:45 Abstract #4
2:45–3:10 Anti-Angiogenic Therapy for the Treatment of Renal Cell Carcinoma
EricJonasch,MD
3:10–3:35 Vascular Disrupting Agents GordonRustin,MD
3:35 Adjourn
Saturday, February 2, 2013 7:30–8:00 a.m. Registration/Continental Breakfast
Session V: Clinical Trial Results Moderator:AxelGrothey,MD
8:00–8:05 Introduction AxelGrothey,MD
8:05–8:30 Clinical Overview and Perspectives on Anti-Angiogenic Therapy in CNS Tumors
PatrickY.Wen,MD
8:30–8:55 Antio-Angiogenic Therapy for the Treatment of Neuroendocrine Tumors
JamesC.Yao,MD
8:55–9:10 Abstract #5 9:10–9:35 Anti-Angiogenic Therapy for the Treatment of Lung Cancer CoreyJ.Langer,MD
9:35–10:00 Anti-Angiogenic Therapy for the Treatment of Breast Cancer GeorgeW.Sledge,Jr.,MD
10:00 Closing Remarks
10:15 Adjourn
Registration InformationOn-site registration will be open from 3:00-7:00 p.m. on Wednesday, January 30, 2013, and at 7:30 a.m. on Thursday, January 31. The conference will begin at 8:00 a.m. on Thursday, January 31, and adjourn at 10:15 a.m. on Saturday, February 2. Advance registration is encouraged as space and materials are limited. Please see registration form for applicable fees.
The deadline for advance registration is January 16, 2013.
There are three ways to register:• Mailto:CME/ConferenceManagement–Unit1381,TheUniversityofTexas
MD Anderson Cancer Center, P.O. Box 301439, Houston, TX 77230-1439• Faxto:713-794-1724• On-lineatwww.mdanderson.org/conferences
We accept the following forms of payment:• Check(payablethroughU.S.banksonly)• MoneyOrder• CreditCards(MasterCard,VISA,andAmericanExpress)• Cash(on-siteregistrationonly)
A receipt and confirmation letter will be sent to you within ten working days of receipt of your fee.
The full conference registration fee includes the tuition, breaks, lunch, and poster reception.
Refund/Cancellation Policy: The registration fee, minus a $50 administrative handling fee, is refundable if a written request is received on or before January 16, 2013. No refunds will be granted after that date. The request for a registration refund must include the tax identification number of the company or institution if registration was paid by a company or institution check.
TheDepartmentofCME/ConferenceManagementreservestherighttocancelactivities prior to the scheduled date, if low enrollment or other circumstances make it necessary. Each registrant will be notified by mail, e-mail, or the contact numbers as given on the registration form.
Incaseofactivitycancellation,liabilityoftheDepartmentofCME/ConferenceManagement is limited to the registration fee. CME/Conference Management will refund the full registrationfee.TheDepartmentofCME/ConferenceManagementreservestherighttolimitthe number of participants in a program and is not responsible for any expenses incurred by an individual whose registration is not confirmed and for whom space is not available.
For additional information, contact CME/Conference Management at 713-792-2223 or toll free at 866-849-5866.
Ghassan K. Abou-Alfa, MDAssociate Attending ProfessorMemorialSloan-Kettering Cancer CenterNew York, New York
Kari Alitalo, MD, PhDResearch Professor of the Academy of FinlandBiomedicumHelsinkiUniversityofHelsinkiHelsinki,Finland
Gabriele Bergers, PhDProfessor Brain Tumor Research CenterUniversity of CaliforniaSan FranciscoSan Francisco, California
Charles D. Blanke, MDVice-PresidentSystemic TherapyBritish Columbia Cancer AgencyProfessor&Chief,MedicalOncologyUniversity of British ColumbiaVancouver, British ColumbiaCanada
Martin Brown, DPhilProfessorStanford UniversityDivisionofRadiationand Cancer BiologyPalo Alto, California
Helen X. Chen, MDSenior Investigator in Cancer TherapyEvaluation ProgramNational Cancer InstituteRockville, Maryland
S. Gail Eckhardt, MDProfessorandDivisionHeadMedicalOncologyStappHarlowChairin Cancer ResearchUniversityofColoradoDenverAurora, Colorado
Lee M. Ellis, MDProfessor of Surgery and Cancer BiologyWilliam C. Liedtke, Jr. Chair in Cancer ResearchThe University of Texas MDAndersonCancerCenterHouston,Texas
Bradley J. Erickson, MD, PhDAssociate Professor of Radiology and InformaticsMayo Medical SchoolMayo ClinicRochester, Minnesota
Michael S. Gordon, MDMedicalOncologyPinnacleOncologyHematologyScottsdale, Arizona
Axel Grothey, MDProfessorofOncologyMayo Clinic College of MedicineRochester, Minnesota
Daniel F. Hayes, MDClinicalDirectorBreastMedicalOncologyProgramStuart B. Padnos Professor in Breast CancerUniversity of Michigan Comprehensive Cancer CenterAnn Arbor, Michigan
Gordon Jayson, MD, PhDProfessorofMedicalOncologyThe University of ManchesterWithington, ManchesterUnitedKingdom
J. Milburn Jessup, MDChief,Diagnostics Evaluation BranchCancerDiagnosisProgramNational Cancer InstituteRockville, Maryland
Eric Jonasch, MDAssociate Professor ofGenitourinaryMedicalOncologyTheUniversityofTexasMDAnderson Cancer CenterHouston,Texas
Robert S. Kerbel, PhDCanada Research Chair in Tumor Biology, Angiogenesis and Anti-Angiogenic TherapyUniversity of TorontoProfessor, Molecular and Cellular Biology ResearchSunnybrookHealthSciences Center/OdetteCancerCenterToronto,Ontario,Canada
Corey J. Langer, MDProfessor of MedicineUniversity of PennsylvaniaPerelman Center for Advanced MedicinePhiladelphia, Pennsylvania
Amita Patnaik, MDAssociateDirectorof Clinical ReserarchSTARTSan Antonio, Texas
Lee S. Rosen, MDProfessor of Clinical MedicineDivisionofHematology-OncologyUniversity of CaliforniaLos Angeles, California
Gordon Rustin, MDDirectorofMedicalOncologyMount Vernon Cancer CentreNorthwood, MiddlesexUnitedKingdom
Bryan P. Schneider, MDAssociate ProfessorIndiana University Melvin and Bren Simon Cancer CenterIndianapolis, Indiana
Gary K. Schwartz, MDChiefMelanoma and Sarcoma ServiceAttending PhysicianMemorialSloan-Kettering Cancer CenterNew York, New York
M. Celeste Simon, PhDProfessor of Cell and DevelopmentalBiologyUniversity of PennsylvaniaHowardHughesMedicalInstitutePhiladelphia, Pennsylvania
George W. Sledge, Jr., MDBallve-LanteroProfessorofOncologyCo-Director,BreastCancerProgramIndiana University Melvin and Bren Simon Cancer CenterIndianapolis, Indiana
Douglas H. Thamm, VMC, DACVIMAssistant Professor andBarbara Cox Anthony Chair inOncologyDirectorofClinicalResearchThe Animal Cancer CenterColorado State University Cancer CenterFort Collins, Colorado
Patrick Y. Wen, MDProfessor of NeurologyHarvardMedicalSchoolDirector,CenterforNeuro-OncologyDanaFarberCancerInstituteBoston, Massachusetts
Max S. Wicha, MDProfessorDepartmentofInternalMedicineDirectorUniversity of MichiganComprehensive Cancer CenterAnn Arbor, Michigan
James C. Yao, MDAssociate ProfessorGIMedicalOncologyThe University of Texas MDAndersonCancerCenterHouston,Texas
Faculty
CO
NFE
RE
NC
E R
EG
IST
RA
TIO
N -
059
7
The 1
5th I
nterna
tiona
l Sym
posiu
m on
Anti
-Ang
iogen
ic Th
erapy
: Re
cent
Adva
nces
and F
uture
Direc
tions
in Ba
sic an
d Clin
ical C
ance
r Res
earch
, Jan
uary
31–
Febru
ary 2,
2013
THIS
IS N
OT A
SEL
F-M
AILE
R
ADDR
ESS
TO:
The 1
5th In
terna
tiona
l Sym
posiu
m on
Anti
-Ang
iogen
ic Th
erapy
: Re
cent
Adva
nces
and F
uture
Direc
tions
in B
asic
and C
linica
l Can
cer R
esea
rch
Depa
rtmen
t of C
ME/
Conf
eren
ce M
anag
emen
t–Un
it 13
81Th
e Un
iver
sity
of T
exas
MD
Ande
rson
Can
cer C
ente
rPO
Box
301
439,
Hou
ston
, TX
7723
0-14
39
or fa
x to
713
-794
-172
4
Mak
e ch
eck
or m
oney
ord
er p
ayab
le to
:Th
e Un
iver
sity
of T
exas
MD
Ande
rson
Can
cer C
ente
r
REG
ISTR
ATI
ON
FEE
S1
Pos
tmar
ked
by 1/
16/1
3 .....
.......
$ 275
.001
Pos
tmar
ked
afte
r 1/1
6/13
........
$ 325
.00
Trai
nees
: 1
Pos
tmar
ked
by 1/
16/1
3 .....
......$
100.0
0 1
Pos
tmar
ked
afte
r 1/1
6/13
.......
$ 150
.00 1
Tra
inee
Sub
mitt
ing
Post
er ...
.$
50.00
Depa
rtmen
t Cha
ir sh
ould
verif
y Tra
inee
stat
us
by si
gnin
g be
low
:
____
____
____
____
____
____
____
____
___
Regi
stra
tion
also
ava
ilabl
e on
-lin
ew
ww
.ant
iang
io20
13.c
om
Special AssistanceContact the Department of CME/Conference Management at 713-792-2223 or toll free at 866-849-5866 if you have any special dietary or ADA accommodation needs.
Accommodations• Ablockofroomshasbeenreservedforconferenceattendeesatthe
Hyatt Regency La Jolla,3777LaJollaVillageDrive,SanDiego,California.• Earlyhotelreservationissuggested.• Thehotelreservationsnumberis858-552-1234.• WhenyoumakereservationsbesuretomentiontheMD Anderson 15th
International Symposium on Anti-Angiogenic Agents to be assured of receiving the special meeting rate of $215.00 single or double occupancy. Please add 12.5% California state and local taxes. Reservations and deposits received after December 28, 2012 will be confirmed if space is available and at current hotel published guest room rates.
Ground TransportationThe hotel is approximately 20 miles from the San Diego International Airport. Taxi rates are approximately $45 one way.
TheUniversityofTexasMDAndersonCancerCenterhasimplementedaprocesswherebyeveryonewhoisin a position to control the content of an educational activity must disclose all relevant financial relationships withanycommercialinterestthatcouldpotentiallyaffecttheinformationpresented.MDAndersonalsorequires that all faculty disclose any unlabeled use or investigational use (not yet approved for any purpose) of pharmaceutical and medical device products. Specific disclosure will be made to the participants prior to the educational activity.
Agendas are subject to change because we are always striving to improve the quality of your educational experience.MDAndersonmaysubstitutefacultywithcomparableexpertiseonrareoccasionsnecessitatedby illness, scheduling conflicts, and so forth.
Photographing, audio taping and videotaping are prohibited.
Please let us know what specific topics, issues or questions you wish to see addressed or emphasized in this activity. Fax or e-mail CME/Conference Management. All responses will be forwarded to the Program Chairs for consideration. La
st N
ame
Firs
t
MI
Hig
hest
Deg
ree
Depa
rtmen
t (in
clud
e bo
x no
.)
Spe
cial
ty
Inst
itutio
n
Stre
et
City
Sta
te/F
orei
gn C
ount
ry/Z
ip o
r Mai
l Cod
e
Dayt
ime
Phon
e (w
ith a
rea
code
)
Ce
ll Ph
one
(with
are
a co
de)
Fax
(with
are
a co
de)
E-m
ail A
ddre
ss
E
mer
genc
y Co
ntac
t
P
hone
(with
are
a co
de)
Char
ge th
e fo
llow
ing:
o
VISA
o
Mas
terC
ard
oAm
eric
an E
xpre
ss
Cred
it Ca
rd N
umbe
r or M
D An
ders
on In
terd
epar
tmen
tal T
rans
fer (
IDT)
No.
Expi
ratio
n Da
te
Cred
it Ca
rd H
olde
r Nam
e (F
irst/L
ast)
C
redi
t Car
d Ho
lder
Bill
ing
Addr
ess
& Z
IP C
ode
Auth
orize
d Si
gnat
ure
REQU
IRED
for c
redi
t car
d or
IDT
MD
Ande
rson
Em
ploy
ee ID
No.
(REQ
UIRE
D)
IDT
Appr
over
Nam
e (F
irst/L
ast)
plea
se p
rint
IDT
Appr
over
E-m
ail
Phys
icia
n
oYe
s o
No
Departm
entofCME/ConferenceManagem
ent-Unit1381
TheUniversityofTexasMDAndersonCancerCenter
# 17
6700
/110
501
POBox301439
Houston,TX77230-1439
Non
-Pro
fit O
rg.
U.S
. Pos
tage
P A
I D
Hou
ston
, TX
Per
mit
No.
705
2